4 year follow-up of Diamyd® Phase II study shows clear positive trend

Diamyd Medical announced today that the company’s 4-year follow-up of type 1 diabetes patients included in the company’s Phase II study shows a clear positive trend.Diamyd Medical received approval from the Swedish Medical Products Agency in February to follow up the children and adolescents with type 1 diabetes that were included in the company’s previously reported Phase II study with the diabetes vaccine Diamyd®. The participants were treated with 2 injections of Diamyd® or placebo; one injection at the study start in 2005 and one injection one month later. Initial analysis of new data